ライフサイエンスコーパス: patients were randomly assigned to receive

1 In the first cohort, 14 patients were randomly assigned to receive 2 mg/kg RG-101 and

2 Patients were randomly assigned to receive 3 times a week eit

3 Between Jan 15, 2011, and Feb 12, 2015, 626 patients were randomly assigned to receive 300 mg intravenous

4 y assigned to receive placebo, and in the second cohort, 14 patients were randomly assigned to receive 4 mg/kg RG-101 and

5 Patients were randomly assigned to receive a family history r

6 Patients were randomly assigned to receive a platelet donatio

7 Patients were randomly assigned to receive a single dose of p

8 In the primary population, 425 patients were randomly assigned to receive atezolizumab and 4

9 Overall, 276 patients were randomly assigned to receive ATRA-ATO or ATRA-C

10 The patients were randomly assigned to receive bivalirudin or hep

11 Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive dacomitinib (n=227

12 Patients were randomly assigned to receive either 45 Gy radio

13 Patients were randomly assigned to receive either catheter ab

14 Seventy-eight patients were randomly assigned to receive either continuous

15 Patients were randomly assigned to receive either EN-EPA (2.2

16 We assessed clinical outcomes 2 years after patients were randomly assigned to receive either endovascula

17 Patients were randomly assigned to receive either intravenous

18 Between April 14, 2005, and July 2, 2009, 460 patients were randomly assigned to receive either lenalidomid

19 Results A total of 4,136 patients were randomly assigned to receive either letrozole (

20 Patients were randomly assigned to receive either pregabalin

21 Patients were randomly assigned to receive evolocumab (either

22 Between Feb 10, 2012, and Jan 30, 2013, 61 patients were randomly assigned to receive fevipiprant (n=30)

23 Patients were randomly assigned to receive follow-up care via

24 Patients were randomly assigned to receive four cycles of 100

25 Patients were randomly assigned to receive IFN alpha-2b at 20

26 Aug 27, 2012, and and the data cutoff of March 8, 2016, 326 patients were randomly assigned to receive inotuzumab ozogami

27 Of the 60 patients recruited, 29 patients were randomly assigned to receive KGF and 31 to plac

28 Patients were randomly assigned to receive levosimendan (in a

29 Between Aug 1, 2010, and May 31, 2013, 26 patients were randomly assigned to receive liraglutide and 26

30 2 were recruited between Nov 4, 2013, and June 9, 2015; 553 patients were randomly assigned to receive naldemedine (n=277

31 tween May 29, 2014, and July 31, 2015, and subsequently 361 patients were randomly assigned to receive nivolumab (n=240)

32 Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2

33 Patients were randomly assigned to receive norethandrolone 10

34 From April 3, 2014, to Dec 4, 2015, 667 patients were randomly assigned to receive placebo (n=286), e

35 least 5 days' withdrawal from all antipsychotic medication, patients were randomly assigned to receive placebo or 32 mg/d

36 A total of 88 patients were randomly assigned to receive placebo or active

37 After birth, patients were randomly assigned to receive placebo or hydroco

38 ts were randomly assigned to receive 2 mg/kg RG-101 and two patients were randomly assigned to receive placebo, and in th

39 ts were randomly assigned to receive 4 mg/kg RG-101 and two patients were randomly assigned to receive placebo.

40 Feb 11, 2015, of 173 patients assessed for eligibility, 74 patients were randomly assigned to receive ruxolitinib and 75

41 Between Feb 21, 2013, and Aug 3, 2015, 5580 patients were randomly assigned to receive SAP early (2798 pa

42 Between Feb 1, 2013, and July 29, 2016, 142 patients were randomly assigned to receive simvastatin (n=71)

43 Patients were randomly assigned to receive single subcutaneou

44 Patients were randomly assigned to receive specialist medical

45 Patients were randomly assigned to receive standard chemother

46 ts were randomly assigned to receive TC6 regimens and 2,117 patients were randomly assigned to receive TaxAC regimens.

47 Results A total of 2,125 patients were randomly assigned to receive TC6 regimens and 2

48 Two hundred twenty-one patients were randomly assigned to receive three CLARA or thr

49 Between May 17, 2013, and Dec 4, 2014, 571 patients were randomly assigned to receive tremelimumab (n=38

50 In 2010-2014, 146 patients were randomly assigned to receive venesections with